









Markets
/
Stocks
/
nasdaq-abbv
/

AbbVie Inc

ABBV

211.960USD

-6.080-2.79%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

374.42BMarket Cap

158.79P/E TTM



AbbVie Inc

211.960

-6.080-2.79%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

More Details of AbbVie Inc Company

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

AbbVie Inc Info



Ticker SymbolABBV

Company nameAbbVie Inc

IPO dateJan 02, 2013

CEOMr. Robert A. Michael, CPA

Number of employees55000

Security typeOrdinary Share

Fiscal year-endJan 02

Address1 N Waukegan Rd

CityNORTH CHICAGO

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code60064

Phone18479327900

Websitehttps://www.abbvie.com/

Ticker SymbolABBV

IPO dateJan 02, 2013

CEOMr. Robert A. Michael, CPA

Company Executives of AbbVie Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+4.33%

Ms. Melody B. Meyer

Independent Director

16.50K

+7.87%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-77.61%

Ms. Jennifer L. Davis

Independent Director

2.52K

+91.00%

Name

Name/Position

Position

Shareholding

Change

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Immunology-SKYRIZI

4.42B

28.20%

Immunology-RINVOQ

2.03B

12.93%

Immunology-HUMIRA

1.18B

7.52%

Hematologic Oncology-IMBRUVICA

965.00M

6.15%

Neuroscience-Botox Therapeutic

928.00M

5.92%

Other

6.16B

39.27%

By RegionUSD

Name

Revenue

Proportion

United States

11.34B

72.31%

International

3.48B

22.18%

All other countries

603.00M

3.84%

Collaboration revenue

260.00M

1.66%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Immunology-SKYRIZI

4.42B

28.20%

Immunology-RINVOQ

2.03B

12.93%

Immunology-HUMIRA

1.18B

7.52%

Hematologic Oncology-IMBRUVICA

965.00M

6.15%

Neuroscience-Botox Therapeutic

928.00M

5.92%

Other

6.16B

39.27%

Shareholding Stats

Updated: Sun, Aug 17

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

9.99%

BlackRock Institutional Trust Company, N.A.

5.21%

State Street Investment Management (US)

4.53%

Geode Capital Management, L.L.C.

2.22%

JP Morgan Asset Management

2.12%

Other

75.93%

Shareholders

Proportion

The Vanguard Group, Inc.

9.99%

BlackRock Institutional Trust Company, N.A.

5.21%

State Street Investment Management (US)

4.53%

Geode Capital Management, L.L.C.

2.22%

JP Morgan Asset Management

2.12%

Other

75.93%

Shareholder Types

Shareholders

Proportion

Investment Advisor

43.55%

Investment Advisor/Hedge Fund

19.97%

Research Firm

3.07%

Bank and Trust

2.30%

Pension Fund

2.21%

Sovereign Wealth Fund

1.40%

Hedge Fund

1.28%

Insurance Company

0.69%

Family Office

0.20%

Other

25.33%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

5286

1.32B

74.49%

-7.96M

2025Q2

5271

1.32B

74.93%

+10.38M

2025Q1

5332

1.32B

74.90%

+11.71M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.30B

73.54%

-7.44M

2024Q2

4916

1.30B

73.53%

+2.27M

2024Q1

4930

1.29B

72.58%

-1.47M

2023Q4

4882

1.28B

72.31%

-1.48M

2023Q3

4694

1.27B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.42M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

176.50M

9.99%

+3.35M

+1.94%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

92.10M

5.21%

+1.07M

+1.18%

Jun 30, 2025

State Street Investment Management (US)

80.02M

4.53%

+61.16K

+0.08%

Jun 30, 2025

Geode Capital Management, L.L.C.

39.18M

2.22%

+924.76K

+2.42%

Jun 30, 2025

JP Morgan Asset Management

37.47M

2.12%

+1.87M

+5.24%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

26.78M

1.52%

+1.52M

+6.01%

Jun 30, 2025

Capital Research Global Investors

25.27M

1.43%

-8.24M

-24.60%

Jun 30, 2025

Morgan Stanley Smith Barney LLC

23.51M

1.33%

+254.93K

+1.10%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

23.10M

1.31%

-1.99M

-7.94%

Jun 30, 2025

Fidelity Management & Research Company LLC

19.65M

1.11%

-1.78M

-8.30%

Jun 30, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

iShares ESG Aware MSCI USA Value ETF

12.4%

Proshares Ultra Health Care

8.16%

iShares U.S. Healthcare ETF

8.12%

Health Care Select Sector SPDR Fund

8.11%

First Trust NASDAQ Pharmaceuticals ETF

8.08%

JPMorgan Healthcare Leaders ETF

7.39%

Fidelity MSCI Health Care Index ETF

7.06%

Themes US Cash Flow Champions ETF

6.78%

Simplify Health Care ETF

6.75%

iShares Core High Dividend ETF

6.32%

iShares ESG Aware MSCI USA Value ETF

Proportion12.4%

Proshares Ultra Health Care

Proportion8.16%

iShares U.S. Healthcare ETF

Proportion8.12%

Health Care Select Sector SPDR Fund

Proportion8.11%

First Trust NASDAQ Pharmaceuticals ETF

Proportion8.08%

JPMorgan Healthcare Leaders ETF

Proportion7.39%

Fidelity MSCI Health Care Index ETF

Proportion7.06%

Themes US Cash Flow Champions ETF

Proportion6.78%

Simplify Health Care ETF

Proportion6.75%

iShares Core High Dividend ETF

Proportion6.32%

Dividend



A total of 48.58B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

KeyAI

